Meet Geoffrey Parker, the Chief Financial Officer and Executive Vice President at Allogene Therapeutics. With a strong background in finance, he brings valuable experience to the company. Geoffrey graduated from Dartmouth College with a double major in Economics and Engineering...

Number of Employees

361

Year

2023

Total Compensation

$2.42M

Salary

$724.00K

Board Justification

The compensation philosophy is designed to align executive compensation with performance and long-term shareholder value, with a significant portion of compensation tied to equity awards and performance metrics.

Bonus

$270.60K

Board Justification

Annual performance-based cash incentive earned for the year 2023, based on corporate goals achievement.

Other

$0.00

Board Justification

No additional compensation reported for 2023.

Restricted Stock

$1.43M(444.11K RSU)

Board Justification

Restricted Stock Units (RSUs) that vest 25% annually over four years, with 444,107 shares vested in 2023.

Performance Metrics

Performance metrics include achieving corporate goals related to clinical development and operational performance.

SEC Filing

From April 23, 2024

Geoffrey Parker

CEO of Allogene Therapeutics

A

Education

B.A. in Economics and Engineering Sciences from Dartmouth College; MBA from Stanford Graduate School of Business

Field of Expertise

Finance & Banking - Finance

Born

January 1, 1965 - 60 years ago

Is Founder?

No

Current Tenure

1 year 3 months (Oct 2023 - Present)

Previous Experience

Chief Operating Officer, Chief Financial Officer and Executive Vice President of Tricida, Inc.